Leerink Partners reiterates Outperform on Eli Lilly (LLY) following orforglipron approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1179.27 +9.67 (0.83%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1169.60 | 52 Week High | $88.16 | |||
| Open | $1153.56 | 52 Week Low | $67.88 | |||
| Day High | $1179.82 | P/E | 272.98 | |||
| Day Low | $1151.67 | EPS | $4.32 | |||
| Volume | 1,392,799 | |||||
